Evaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD)
Abstract Background Our meta-analysis fills gaps by assessing sodium-glucose cotransporter-2 (SGLT2) inhibitors’ renal outcomes in chronic kidney disease (CKD) patients including long-term effects and the subgroup analyses of estimated glomerular filtration rate (eGFR) values and follow-up times. Me...
Saved in:
Main Authors: | Min-Jia Cao, Ting-Ting Liang, Li Xu, Fang-Hong Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Diabetology & Metabolic Syndrome |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13098-024-01547-x |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
by: Kyoung Hwa Ha, et al.
Published: (2025-02-01) -
Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia
by: Yuri Sakai Ishizaki, et al.
Published: (2024-11-01) -
Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01) -
Association of sodium–glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: a systematic review and meta-analysis
by: Michele Maremmani, et al.
Published: (2025-01-01) -
Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?—a cross sectional analysis of a nationwide Japanese claims database
by: Go Anan, et al.
Published: (2023-11-01)